Clearpoint Neuro Inc

Clearpoint Neuro, Inc. engages in the development and commercialization of platforms for performing minimally invasive surgical procedures in the brain and heart. The firm conducts its procedures under direct, intra-procedural magnetic resonance imaging guidance. Its product platform consists of the ClearPoint system and ClearTrace system. The company was founded by Paul A. Bottomley on March 12, 1998 and is headquartered in Solana Beach, CA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

ClearPoint Neuro reports revenue growth, faces margin pressures in 2022

ClearPoint Neuro's financial performance in 2022 showed revenue growth but faced margin pressures and increased operating expenses.
The company's strengths lie in revenue growth projections, successful product launches, and cost-saving initiatives.
Challenges include post-COVID operational disruptions, supply chain concerns, and achieving cash breakeven targets.
Opportunities exist in R&D investments, international expansion, and maintaining an optimistic outlook for future growth.

ClearPoint Neuro reports Q1 growth, targets $50M revenue by 2025

ClearPoint Neuro Inc's Q1 performance reflects steady revenue growth and strategic investments to drive future expansion and innovation.
While facing challenges in certain revenue segments and margin decline, the company's strong growth strategy and focus on key areas present opportunities for sustained success.
With a clear roadmap to achieve revenue targets, expand partnerships, and launch new products, ClearPoint is poised for continued growth and market leadership in the neurosurgery sector.

ClearPoint Neuro reports record revenue and growth strategy focus

ClearPoint Neuro Inc's Q2 2023 earnings call highlighted record revenue, growth pillars, and operational efficiency improvements. Challenges include installation barriers and regulatory expansions, while opportunities lie in neuro-oncology expansion and pharma partnerships. The company aims for cash flow breakeven by 2025 and emphasizes long-term pharma relationships.

ClearPoint Neuro reports improved Q3 performance amidst strategic growth plans

ClearPoint Neuro's Q3 2023 performance showed improvements in operational cash burn and revenue growth in key segments, despite challenges in gross margin and operating expenses.
The company's strategic focus on innovation, patient outcomes, and market expansion presents opportunities for sustained growth and competitiveness in the healthcare sector.
While facing challenges in cost management and market access, ClearPoint Neuro is well-positioned to leverage opportunities in new revenue streams, product launches, and operational enhancements.
Overall, ClearPoint Neuro's commitment to improving patient outcomes, expanding market reach, and driving innovation underscores its potential for future success and growth.

ClearPoint Neuro reports robust Q4 earnings, eyes growth opportunities

ClearPoint Neuro's strong Q4 performance and revenue growth in 2023 position the company well for 2024. Despite challenges with EU MDR certification, ClearPoint is investing in partnerships to overcome regulatory hurdles. Opportunities for growth include new product releases and expanding market presence.

ClearPoint Neuro reports 41% revenue growth in Q1 2024

ClearPoint Neuro's Q1 2024 earnings call showcased robust revenue growth, controlled expenses, and a strategic focus on key growth areas. The company's optimistic outlook for 2024 is supported by strong demand from pharmaceutical partners and expansion initiatives.

ClearPoint Neuro reports record revenue growth and raises full-year guidance

ClearPoint Neuro's Q2 2024 performance reflects robust revenue growth and a solid financial position.
The company's focus on key growth pillars and increased revenue guidance for the year signal a positive outlook for future expansion.
While challenges in cost management and market competition exist, ClearPoint Neuro's strengths and opportunities position it well for sustained growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

ClearPoint Neuro's (CLPT) receipt of the FDA's latest approval is likely to serve a wider patient pool than its legacy portfolio.

ClearPoint Neuro (CLPT) Gets FDA's Nod for SmartFrame OR System

Aehr Test Systems

AST SpaceMobile

ChargePoint Holdings

Enovix Corporation

Jumia

Rocket Lab USA

Small-cap stocks are set to have their day in the sun this year, and not just because favorable economic and monetary policy conditions are set to put wind in their sales. Instead, investors are increasingly nervous about the high-flying large- and mega-cap tech stocks that beat all odds to rally substantially in 2023.

7 Small-Cap Stocks With Huge Potential Flying Under the Radar

SOLANA BEACH, Calif., Jan. 08, 2024 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced preliminary, unaudited financial results for its fourth quarter and full year ended December 31, 2023. These preliminary unaudited financial results are management's estimates and are subject to revision in the course of completing annual audit processes. Audited results for 2023 will be publicly reported by the Company later in the first quarter of 2024, prior to a Form 10-K filing for the year with full financial statements.

ClearPoint Neuro Reports Fourth Quarter and Full Year 2023 Preliminary Revenue Results and Guidance for Full Year 2024 Revenue

The mean of analysts' price targets for ClearPoint Neuro, Inc. (CLPT) points to a 48.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

How Much Upside is Left in ClearPoint Neuro, Inc. (CLPT)? Wall Street Analysts Think 48.77%

Aspen Aerogels

Lemonade

Planet Labs

I think 2024 will be the year small-cap stocks win big. We're already seeing tailwinds lift the stock market closer to past highs, but (valid) criticism points to just a handful of mega-cap stocks driving most of the momentum.

7 Solid Small-Caps for 2024 and Beyond

NeuroOne Medical Technologies Corp

Both NeuroOne and ClearPoint Neuro are emerging as significant players in the neurological device sector, each carving out their own niche, with ClearPoint focusing on drug delivery and NeuroOne advancing. NeuroOne is rapidly positioning itself as a formidable competitor in the brain drug delivery market, a niche where ClearPoint Neuro has established a strong foothold, indicating a potential shift. NeuroOne's ongoing strategic initiatives, including partnerships and product development, coupled with its improving financial health, present it as an attractive investment opportunity.

NeuroOne: A Hidden Contender Against ClearPoint In The Brain Drug Delivery Arena

ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q3 2023 Earnings Conference Call November 9, 2023 4:30 PM ET Company Participants Joe Burnett - Chief Executive Officer Danilo D'Alessandro - Chief Financial Officer Conference Call Participants Mathew Blackman - Stifel William Wood - B. Riley Frank Takkinen - Lake Street Capital Markets Operator Thank you for standing by, and welcome to the ClearPoint Neuro, Inc. Q3 2023 Earnings Conference Call.

ClearPoint Neuro, Inc. (CLPT) Q3 2023 Earnings Call Transcript

ClearPoint Neuro, Inc. (CLPT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ClearPoint Neuro, Inc. (CLPT) Expected to Beat Earnings Estimates: Should You Buy?

SOLANA BEACH, Calif., Oct. 26, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2023 third quarter on Thursday, November 9, after the market close.

ClearPoint Neuro to Announce Third Quarter 2023 Results November 9, 2023

ClearPoint Neuro has shown steady improvement in quarterly revenue growth, particularly in the biologics and drug delivery segment. Given that this is the most important company segment, this growth is encouraging for future success. While risks abound, I continue to rate CLPT stock a Buy.

ClearPoint Neuro Continues To Make Progress

SOLANA BEACH, Calif., July 25, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2023 second quarter on Tuesday, August 8, after the market close.

ClearPoint Neuro to Announce Second Quarter 2023 Results August 8, 2023

Belite Bio Inc

Cooper Companies

iRhythm Technologies

STAAR Surgical

The most oversold stocks in the health care sector presents an opportunity to buy into undervalued companies.

Top 5 Health Care Stocks That Are Set To Fly In Q2

ClearPoint Neuro's progress on its four-pillar strategy continues despite a challenging operating environment, with an increasing number of partners and hospital sites featuring its equipment. The company has entered into pre-clinical work and milestone-based partnerships, such as its recent deal with UCB, a global biopharmaceutical leader. However, ClearPoint Neuro faces challenges with its cash position and increased cash burn, which may prevent current stockholders from benefiting financially from eventual profitability.

ClearPoint Neuro: I Continue To Rate The Stock A 'Buy'

Terran Orbital Corp

PacWest Bancorp

When looking for big winners in the stock market, smaller is better. A gigantic firm like Apple (NASDAQ: AAPL ) can realistically only go up so much in a given time period.

3 High-Potential Small-Cap Stocks for Investors With Strong Stomachs

SOLANA BEACH, Calif., May 24, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it has entered into a multi-year license agreement with UCB (EURONEXT BRUSSELS: UCB), a global biopharmaceutical leader, to partner on drug delivery platforms for UCB's gene therapy portfolio.

ClearPoint Neuro and UCB Enter License Agreement for Gene Therapy Drug Delivery

SOLANA BEACH, Calif., May 18, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (Nasdaq: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, announced today that its management will present at the B. Riley Securities 2023 Institutional Investor Conference on Wednesday, May 24, 2023 at 8:15 a.m. Pacific Time.

ClearPoint Neuro to Present at the B. Riley Securities 2023 Institutional Investor Conference

ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q1 2023 Results Conference Call May 11, 2023 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D'Alessandro - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Operator Greetings, and welcome to the ClearPoint Neuro Inc. First Quarter 2023 Financial Results Conference Call. At this time, all participants are in a listen only mode.

ClearPoint Neuro, Inc. (CLPT) Q1 2023 Earnings Call Transcript

SOLANA BEACH, Calif., May 10, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced it will present investigational research and exhibit at the 26th American Society of Gene and Cell Therapy being held in Los Angeles, CA from May 16 to May 20.

ClearPoint Neuro to Present Investigational Research and Showcase Novel Innovations at the 26th American Society of Gene & Cell Therapy Annual Meeting in Los Angeles

SOLANA BEACH, Calif., April 28, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced that it will release financial results for its 2023 first quarter on Thursday, May 11, after the market close.

ClearPoint Neuro to Announce First Quarter 2023 Results May 11, 2023

Charles River Laboratories

Danaher

It's been a rocky market for growth stocks over the past 18 months. We've seen a flurry of layoffs and spending cutbacks from leading tech companies.

3 Healthcare Stocks With Huge Growth Potential

SOLANA BEACH, Calif., April 18, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced an exclusive worldwide agreement with NE Scientific, LLC, a leader in biophysics simulation, to develop a GPU-accelerated software solution for modeling of drug infusions delivered with the ClearPoint SmartFlow® cannula. Under the terms of the agreement, this first of many software collaborations will enable simulation of patient-specific infusion in real time to predict the distribution of therapeutic agents in 4D before the actual procedure. Coupled with Maestro, this new software will allow optimization of infusion parameters including target points, flow rate, infusion coverage and leakage outside of target-specific boundaries. The simulation software will require standard structural and diffusion pre-operative MRI scans. Infusions can be planned either in the pre-operative MRI space and registered to intra-operative MRI case data, or in the OR space using an intra-operative CT.

ClearPoint Neuro Announces Agreement with NE Scientific to Integrate Gene Therapy Infusion Coverage Tool into ClearPoint Maestro® Brain Model

SOLANA BEACH, Calif., April 13, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced successful registration of its Neuro Navigation portfolio with the Brazilian regulatory body, Agência Nacional de Vigilância Sanitária (ANVISA).

ClearPoint Neuro Announces ANVISA Approval of Neuro Navigation Portfolio in Brazil

SOLANA BEACH, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced further expansion of its worldwide license and research agreement with Philips, a global leader in health technology, to add subnuclei segmentation applied to MRI, and potentially CT scans, for use in the operating room. The design goal of the ClearPoint Maestro® Brain Model is to enable highly accurate ClearPoint interventions under both MRI and CT guidance by facilitating patient-specific, multi-modal fusion for accurate target identification and trajectory planning.

ClearPoint Neuro Extends Software License and Research Agreement with Philips to Include Fully Automatic Subnuclei Segmentation for DBS

SOLANA BEACH, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- ClearPoint Neuro, Inc. (NASDAQ: CLPT) (the “Company”), a global therapy-enabling platform company providing navigation and delivery to the brain, today announced an exclusive multi-year licensing agreement of intellectual property from UC San Francisco (UCSF) through its Innovation Ventures group to develop and commercialize a radially branching cellular delivery device for use both in the Operating Room under fluoroscopy/CT guidance and under MRI guidance.

ClearPoint Neuro Announces Exclusive Multi-Year Licensing Agreement with UCSF for Innovative Intra-Cerebral Cellular Delivery Platform

ClearPoint Neuro, Inc. (NASDAQ:CLPT ) Q4 2022 Earnings Conference Call March 1, 2023 4:30 PM ET Company Participants Joe Burnett - CEO Danilo D'Alessandro - CFO Conference Call Participants Frank Takkinen - Lake Street Capital Markets Neil Chatterji - B. Riley Financial Operator Greetings, and welcome to the ClearPoint Neuro Fourth Quarter and Full Year 2022 Financial Results Conference Call.

News for Clearpoint Neuro Inc Stock (CLPT)